IR 780 (Synonyms:碘化物;IR-780 碘化物;11-氯-1,1 -二正丙基-3,3,3 ,3 -四甲基-10,12-三亚甲基吲哚三碳花青碘盐;11-氯-1,1'-二正丙基-3,3,3',3'-四甲基-10,12-三亚甲基吲哚三碳花青碘盐;碘化物(IR-780 碘化物);2-[2-[2-氯-3-[(1,3-二氢-3,3-二甲基-1-丙基-2H-吲哚-2-亚基)亚乙基]-1-环己烯-1-基]乙烯基]-3,3-二甲基-1-丙基吲哚鎓碘化物)
目录号 : KCM12472 CAS No. : 207399-07-3 纯度 : ≥98%
IR 780 is a heptamethine cyanine fluorescent probe for in vivo imaging of tumor cells. It displays excitation/emission maxima of 780/799 nm, respectively. IR 780 is transported into tumor cells, an effect that can be blocked by the organic anion transporting polypeptide (OATP) inhibitor sulfobromophthalein (bromosulfalein; ), and targeted to the mitochondria. It has an additive effect on the increase in reactive oxygen species (ROS) production induced by sonodynamic therapy (SDT) in 4T1 breast cancer cells when used at a concentration of 16 µM. IR 780 (0.2 mg/kg, i.v.) preferentially accumulates in tumor tissue in MCF-7, HeLa, and MG-63 mouse xenograft models and in a syngeneic mouse model of chemically induced lung tumors, and its fluorescence is detectable for up to 20 days. It also has an additive effect on the SDT-induced reduction in tumor growth in an 4T1 murine mammary carcinoma model. IR 780 has been incorporated into heparin-folic acid-IR 780 nanoparticles for use in photothermal therapy.
规格 价格 是否有货 数量
500mg
In-stock
1g
In-stock
KKL Med 的所有产品和服务仅用于科学研究,不能被用于人体,兽医,我们也不向个人提供产品和服务。
分子式
C36H44CliN2
分子量
667.11
CAS号
207399-07-3
中文名称
IR-780 碘化物
储存方式
Powder -20°C 3 years
  4°C 2 years
In solvent -80°C 6 months
  -20°C 1 month
溶解性数据
In Vitro:

DMSO : 12.5 mg/mL (18.74 mM; ultrasonic and warming and heat to 60°C)

配制储备液
浓度 溶剂体积 质量 1 mg 5 mg 10 mg
1 mM 1.4990 mL 7.4950 mL 14.9900 mL
5 mM 0.2998 mL 1.4990 mL 2.9980 mL
10 mM 0.1499 mL 0.7495 mL 1.4990 mL
*

请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效。
储备液的保存方式和期限:-80°C, 6 months; -20°C, 1 month。-80°C 储存时,请在 6 个月内使用,-20°C 储存时,请在 1 个月内使用。

In Vivo:

请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照 In Vitro 方式配制澄清的储备液,再依次添加助溶剂:

——为保证实验结果的可靠性,澄清的储备液可以根据储存条件,适当保存;体内实验的工作液,建议您现用现配,当天使用; 以下溶剂前显示的百
分比是指该溶剂在您配制终溶液中的体积占比;如在配制过程中出现沉淀、析出现象,可以通过加热和/或超声的方式助溶

  • 1.

    请依序添加每种溶剂: 10% DMSO → 40% PEG300 → 5% Tween-80 → 45% saline

    Solubility: ≥ 1.25 mg/mL (1.87 mM); Clear solution

    此⽅案可获得 ≥ 1.25 mg/mL (1.87 mM,饱和度未知) 的澄清溶液。

    以 1 mL ⼯作液为例,取 100 μL 12.5 mg/mL 的澄清 DMSO 储备液加到 400 μL PEG300 中,混合均匀;向上述体系中加⼊ 50 μ L Tween-80,混合均匀;然后继续加⼊ 450 μL ⽣理盐⽔定容⾄ 1 mL。

     
  • 2.

    请依序添加每种溶剂: 10% DMSO → 90% (20% SBE-β-CD in saline)

    Solubility: 1.25 mg/mL (1.87 mM); Suspended solution; Need ultrasonic

    此⽅案可获得 1.25 mg/mL (1.87 mM) 的均匀悬浊液,悬浊液可⽤于⼝服和腹腔注射。

    以 1 mL ⼯作液为例,取 100 μL 12.5 mg/mL 的澄清 DMSO 储备液加到 900 μL 20% 的 SBE-β-CD ⽣理盐⽔⽔溶液中,混合均 匀。

The molarity calculator equation
Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)
The dilution calculator equation
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
This equation is commonly abbreviated as: C1V1 = C2V2